MarketInOut Stock Screener Log In | Sign Up
 

ALK-Abello A/S Series B

VIE • Healthcare • Biotechnology • Quote as of 05/12/2026 17:32
ALK-Abello A/S Series B stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeVIE
Market Capitalization7,626.94 mln
Float132 mln
Earnings Date05/05/2026

EPS

0.77
Stretched

P / E

43.74
High premium

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

-2.34
Borderline

Relative Strength

90 / 100
Top performer

Debt / Equity

0.06
Debt-free

Business Description

Founded in 1923 and based in Hørsholm, Denmark, ALK-Abelló is a medical company focused on helping people with allergies live better lives. It develops and sells a broad range of allergy treatments, including tablets, injections, nasal sprays, and biologics targeting conditions such as hay fever, house dust mite allergy, peanut allergy, and life-threatening anaphylaxis. The company also offers diagnostic tools and a digital platform to help patients identify and manage their allergies, and it operates across Europe, North America, Asia, and beyond through its own commercial network and partnerships with other pharmaceutical firms.

Key Fundamentals

EPS0.77
P/E43.74
ROE20.83
RPS3.98
ROIC19.68
ROA14.78
Interest Cover60.46
EBITDA, mln282
EV / EBITDA28.08
EV / EBIT33.61
Revenue, mln879
EV / Revenue8.88

Financial Strength

Altman Z-Score14.15
Piotroski F-Score 7 / 9
Beneish M-Score-2.34
Price to Lynch Fair Value1.91
Price to Graham Number4.81
Shiller PE Ratio166

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.5% 26 / 100   
1 Month 17.91% 91 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us